Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ajem.2024.11.095 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Use of diltiazem for acute rate control in the emergency department.
Am J Emerg Med
December 2024
Department of Emergency Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan. Electronic address:
Discovering Severe Adverse Reactions From Pharmacokinetic Drug-Drug Interactions Through Literature Analysis and Electronic Health Record Verification.
Clin Pharmacol Ther
November 2024
Department of Biomedical Informatics, School of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
While drug-drug interactions (DDIs) and their pharmacokinetic (PK) mechanisms are well-studied prior to drug approval, severe adverse drug reactions (SADRs) caused by DDIs often remain underrecognized due to limitations in pre-marketing clinical trials. To address this gap, our study utilized a literature database, applied natural language processing (NLP) techniques, and conducted multi-source electronic health record (EHR) validation to uncover underrecognized DDI-SADR signals that warrant further investigation. PubMed abstracts related to DDIs from January 1962 to December 2023 were retrieved.
View Article and Find Full Text PDFA retrospective observational study of certain interactions with simvastatin 40 mg in an acute hospital in England.
Br J Cardiol
May 2024
Head of Prescribing Support Unit Pharmacy Department, Royal Cornwall Hospitals NHS Trust, Truro, Cornwall, TR1 3LJ.
The use of simvastatin 40 mg with various interacting medicines may lead to an increased risk of myopathy. We examined the extent to which hospital inpatients were prescribed simvastatin 40 mg with amiodarone, amlodipine, diltiazem, or verapamil, and assessed if any action was taken by prescribers or the pharmacy team to avoid this interaction. We found 56 patients on a combination of interest during their stay.
View Article and Find Full Text PDFComparative safety and efficacy of a hybrid intravenous and oral diltiazem protocol for acute rate control in the emergency department.
Am J Emerg Med
November 2024
School of medicine, University of Galway, Ireland.
Diltiazem mitigates acute liver injury by targeting NFκB-TXNIP/NLRP3 axis in Rats: New insights beyond calcium channel blockade.
Int Immunopharmacol
December 2024
Department of Pharmacology, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa 11152, Egypt. Electronic address:
Acute liver injury is characterized by the rapid onset of inflammation in the liver, which in turn plays a role in the development of hypertension. Additionally, hypertension increases susceptibility to liver diseases associated with inflammatory states. Recently, the antihypertensive drug diltiazem has demonstrated anti-inflammatory properties and has been shown to inhibit the expression of the thioredoxin-interacting protein (TXNIP), an upstream regulator of the NOD-like receptor pyrin-3 (NLRP3) inflammasome pathway.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!